741 related articles for article (PubMed ID: 21676290)
1. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
Agarwal S; Sane R; Oberoi R; Ohlfest JR; Elmquist WF
Expert Rev Mol Med; 2011 May; 13():e17. PubMed ID: 21676290
[TBL] [Abstract][Full Text] [Related]
2. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
3. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
Becker CM; Oberoi RK; McFarren SJ; Muldoon DM; Pafundi DH; Pokorny JL; Brinkmann DH; Ohlfest JR; Sarkaria JN; Largaespada DA; Elmquist WF
Neuro Oncol; 2015 Sep; 17(9):1210-9. PubMed ID: 25972455
[TBL] [Abstract][Full Text] [Related]
4. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.
Agarwal S; Manchanda P; Vogelbaum MA; Ohlfest JR; Elmquist WF
Drug Metab Dispos; 2013 Jan; 41(1):33-9. PubMed ID: 23014761
[TBL] [Abstract][Full Text] [Related]
5. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
6. Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of glioma.
Zhang F; Xu CL; Liu CM
Drug Des Devel Ther; 2015; 9():2089-100. PubMed ID: 25926719
[TBL] [Abstract][Full Text] [Related]
7. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
Oberoi RK; Parrish KE; Sio TT; Mittapalli RK; Elmquist WF; Sarkaria JN
Neuro Oncol; 2016 Jan; 18(1):27-36. PubMed ID: 26359209
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
9. Bioenergetics pathways and therapeutic resistance in gliomas: emerging role of mitochondria.
Griguer CE; Oliva CR
Curr Pharm Des; 2011; 17(23):2421-7. PubMed ID: 21827418
[TBL] [Abstract][Full Text] [Related]
10. Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.
Parrish KE; Sarkaria JN; Elmquist WF
Clin Pharmacol Ther; 2015 Apr; 97(4):336-46. PubMed ID: 25669487
[TBL] [Abstract][Full Text] [Related]
11. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.
Choudhury H; Pandey M; Chin PX; Phang YL; Cheah JY; Ooi SC; Mak KK; Pichika MR; Kesharwani P; Hussain Z; Gorain B
Drug Deliv Transl Res; 2018 Oct; 8(5):1545-1563. PubMed ID: 29916012
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model.
Lakkadwala S; Singh J
Colloids Surf B Biointerfaces; 2019 Jan; 173():27-35. PubMed ID: 30261346
[TBL] [Abstract][Full Text] [Related]
13. Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells.
Salaroglio IC; Abate C; Rolando B; Battaglia L; Gazzano E; Colombino E; Costamagna C; Annovazzi L; Mellai M; Berardi F; Capucchio MT; Schiffer D; Riganti C
Mol Pharm; 2019 Aug; 16(8):3361-3373. PubMed ID: 31265310
[TBL] [Abstract][Full Text] [Related]
14. Targeted Vascular Drug Delivery in Cerebral Cancer.
Humle N; Johnsen KB; Arendt GA; Nielsen RP; Moos T; Thomsen LB
Curr Pharm Des; 2016; 22(35):5487-5504. PubMed ID: 27464719
[TBL] [Abstract][Full Text] [Related]
15. Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors.
Talele S; Zhang W; Chen J; Gupta SK; Burgenske DM; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2022 Oct; 383(1):91-102. PubMed ID: 36137710
[TBL] [Abstract][Full Text] [Related]
16. Evolving strategies: future treatment of glioblastoma.
Chamberlain M
Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
[TBL] [Abstract][Full Text] [Related]
17. Highlights in targeted nanoparticles as a delivery strategy for glioma treatment.
Luiz MT; Delello Di Filippo L; Tofani LB; de Araújo JTC; Dutra JAP; Marchetti JM; Chorilli M
Int J Pharm; 2021 Jul; 604():120758. PubMed ID: 34090991
[TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies.
Balça-Silva J; Matias D; Carmo AD; Sarmento-Ribeiro AB; Lopes MC; Moura-Neto V
Semin Cancer Biol; 2019 Oct; 58():130-141. PubMed ID: 30266571
[TBL] [Abstract][Full Text] [Related]
19. Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.
Agarwal S; Mittapalli RK; Zellmer DM; Gallardo JL; Donelson R; Seiler C; Decker SA; Santacruz KS; Pokorny JL; Sarkaria JN; Elmquist WF; Ohlfest JR
Mol Cancer Ther; 2012 Oct; 11(10):2183-92. PubMed ID: 22891038
[TBL] [Abstract][Full Text] [Related]
20. Penetrating the Blood-Brain Barrier by Self-Assembled 3D DNA Nanocages as Drug Delivery Vehicles for Brain Cancer Therapy.
Tam DY; Ho JW; Chan MS; Lau CH; Chang TJH; Leung HM; Liu LS; Wang F; Chan LLH; Tin C; Lo PK
ACS Appl Mater Interfaces; 2020 Jul; 12(26):28928-28940. PubMed ID: 32432847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
